<DOC>
	<DOCNO>NCT02255097</DOCNO>
	<brief_summary>This study single-agent pembrolizumab ( MK-3475 ) participant recurrent and/or metastatic head neck squamous cell carcinoma ( HNSCC ) progress platinum-based cetuximab therapy . The primary study hypothesis pembrolizumab provide clinically meaningful objective response rate ( ORR ) .</brief_summary>
	<brief_title>Study MK-3475 ( Pembrolizumab ) Recurrent Metastatic Head Neck Squamous Cell Carcinoma After Treatment With Platinum-based Cetuximab Therapy ( MK-3475-055/KEYNOTE-055 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologicallyconfirmed recurrent metastatic HNSCC oral cavity , oropharynx , hypopharynx , larynx consider incurable local therapy Tumor progression recurrence within 6 month last dose number platinumbased cetuximab therapy line adjuvant , primary , recurrent , metastatic setting ; must resistant ( respond ) platinum cetuximab Available tissue biomarker analysis Measurable disease base RECIST 1.1 determine central review Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function Female participant childbearing potential must negative urine serum pregnancy test must willing use 2 adequate method contraception start screen visit 120 day last dose pembrolizumab Male participant female partner ( ) childbearing potential must willing use 2 adequate method contraception screen 120 day last dose pembrolizumab Exclusion criterion : Disease suitable local therapy administer curative intent Currently receive treatment study investigational agent use investigational device &lt; = 4 week prior first dose trial medication Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial medication Not recover AEs due previously administer therapy Known additional malignancy progress require active treatment exclude basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy situ cancer Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent Active , noninfectious pneumonitis Active infection require systemic therapy Pregnant , breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial medication Human immunodeficiency virus ( HIV ) Hepatitis B C Received live vaccine within 30 day plan start study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PD-1</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
</DOC>